→ Kura Oncology $KURA has recruited a COO from Celgene. Marine vet John Farnam will leap in from the Celgene Receptos group in San Diego, which has been at the center of considerable speculation in the wake of the FDA’s RTF letter for ozanimod. Farnam has been VP of Business Operations at the Celgene subsidiary. Bridget Martell and Blake Tomkinson have joined the company as Vice Presidents of Clinical Development.
→ TG Therapeutics $TGTX and Novimmune have struck a $185 million deal to develop a bispecific antibody that can simultaneously tackle CD47 and CD19. The partners are touting the work as the first anti-CD47 bispecific that will hit human studies, with the first clinical trial getting started either later this year or early in 2019. They didn’t break out the upfront from the package of milestones, the latter of which likely dominates.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription